TheraRadar
← Back
Data updated: Mar 29, 2026

NATCO PHARMA USA

NeurologyCardiovascular
Generics

NATCO PHARMA USA is a generic drug manufacturer focused on Neurology, Cardiovascular.

2008
Since
5
Drugs
-
Trials
40
Approved (2yr)

Key Drugs

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
hydrochlorothiazide
Cardiovascular
AT1 receptor 1 indications · 2016

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

CARBOPLATIN 2026-02-04
FLUOXETINE HYDROCHLORIDE 2026-01-15
Manufacturing (CMC)
FLUOXETINE HYDROCHLORIDE 2026-01-15
Manufacturing (CMC)
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE 2025-10-10
Labeling
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE 2025-09-30
Labeling
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE 2025-09-30
Labeling
FLUOXETINE HYDROCHLORIDE 2025-09-26
Labeling
FLUOXETINE HYDROCHLORIDE 2025-09-26
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Neurology 50%
1 drugs
Cardiovascular 50%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

GE HEALTHCARE specialty
Neurology, Cardiovascular
Novo Nordisk big-pharma
Cardiovascular, Neurology
LEDERLE big-pharma
Cardiovascular, Neurology
PAI HOLDINGS PHARM big-pharma
Neurology, Cardiovascular
VALIDUS PHARMS specialty
Cardiovascular, Neurology